CPT code 0037U identifies the FoundationOne CDx™ (F1CDx®) proprietary companion diagnostic genomic profiling test from Foundation Medicine, Inc. As a PLA code, 0037U denotes a single manufacturer-specific assay used to detect genomic alterations across multiple tumor indications to guide targeted cancer therapies. Its use is clinically significant as precision oncology testing increasingly influences systemic therapy selection and eligibility for targeted agents and clinical trials.

Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of code definition and clinical intent, payer coverage landscape, and typical sites of service. The publication summarizes benchmark topics relevant to billing and reimbursement for PLA companion diagnostics, notes common modifiers used with laboratory billing, and provides clinical context for the test’s role as a companion diagnostic across five tumor indications.

This summary is intended to inform revenue cycle, laboratory operations, and policy teams about the code’s purpose, how major payers are approached in analyses, and what to expect when managing billing and documentation for a manufacturer-specific CDx laboratory assay.